On May 28, WuXi XDC declined 3.14% in regular trading to HK$55.4 per share, with turnover of approximately HK$28.93 million, marking consecutive sessions of weakness.

On the news front, the company previously announced plans to deploy up to US$100 million in internal funds for open-market share repurchases, while parent company WuXi Biologics also unveiled a buyback plan of up to US$400 million, bringing the combined repurchase scale to US$500 million. However, the intensive buyback programs have failed to effectively restore market confidence. The broader WuXi family of stocks remained under significant pressure, with WuXi AppTec down 3.44% and WuXi Biologics down 2.91% in the same session.

Guotai Junan International maintains an Overweight rating on the company with a target price of HK$84.38, citing optimism on ADC pipeline growth prospects. The company reported backlog orders of approximately US$1.489 billion, up 50.3% year-over-year, with new contract value of US$1.33 billion, up 41% year-over-year.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)